bioAffinity Launches Study with BAMC to Expand CyPath® Lung Sample Options
BIAF sits 62% above its 52-week low of $0.693.
Summary
bioAffinity Technologies announced a new study with Brooke Army Medical Center to validate expanded sample collection options for its CyPath® Lung diagnostic test, aiming to broaden its clinical utility.
Key Events · Product Development and Regulatory · BIAF
-
New Clinical Study Initiated
bioAffinity Technologies announced a new study with Brooke Army Medical Center (BAMC) to validate the use of CyPath® Lung with tracheal and bronchial suctioning samples for early lung cancer detection.
-
Expanding CyPath® Lung Utility
This study aims to broaden the versatility and potential adoption of the CyPath® Lung diagnostic test by validating additional sample collection methods beyond the standard at-home sputum collection.
-
Results Expected Mid-2026
The study is designed to enroll 30-50 patients, with results anticipated by mid-year 2026, which could support broader use of the test.
Analysis · BIAF · Industrial Applications And Services
This filing details a new clinical study aimed at validating additional sample collection methods for CyPath® Lung, potentially broadening its applicability and market reach. For a micro-cap company focused on diagnostics, expanding the utility of its flagship product is a positive step in its commercialization strategy. The collaboration with Brooke Army Medical Center lends credibility to the study. Investors should monitor the progress and results of this study, expected by mid-2026, as successful validation could enhance the product's competitive position and adoption.
At the time of this filing, BIAF was trading at $1.12 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5M. The 52-week trading range was $0.69 to $46.53. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.